Word: bowels
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...have the luxury of flushing the toilet and just seeing it disappear," says George. The industry is stalled not only by that convenience, but by taboo. "People are uncomfortable talking about their own waste." It may have been quite some time since relating the adventures of your most recent bowel movement has constituted acceptable fodder for conversation, but nevertheless, says George, our 'bodily products' have to come back into the conversation somehow, if we are ever going to flush away the flush...
...urinary incontinence drugs have made women aware of the prevalence of the condition and its treatments. Not so for fecal incontinence, says Nygaard, which she calls a "profoundly embarrassing" condition for most patients. It can be attributed to muscle damage during childbirth, but a more common cause is irritable bowel syndrome. Most patients are shocked when they discover just how common prolapse and leakage problems are - about one in 10 women will have surgery to address the disorders, Nygaard says...
...wait for “Archaeology of Harvard Yard” students to find you in twenty years. 2) Load up on a full plate of your dining hall’s Boston Baked Scrod—a surprise in every mouthful could lead to conveniently timed irritable bowel syndrome. 3) Turn off the heat, open the window, and get naked—we call this frostbite for a cause. 4) Participate in a sleep deprivation experiment for psych labs—check into UHS for drooling and hallucinations. 5) Want a free pass on your term paper? Read Faust?...
...indeed. April has always been the cruelest month. Now it is also Irritable Bowel Syndrome Awareness Month. In fact, this last may be the most pressing matter...
That expansion was partly in preparation for the launch of a potential blockbuster drug called Zelnorm, aimed at irritable bowel syndrome, for which there are few treatments. But the FDA, expressing concern about Zelnorm's side effects, rejected the application, asking for more data. In the short term, says Morgan Stanley analyst Duncan Moore, Novartis' prospects for robust growth depend heavily on the FDA's reversing its ruling on Zelnorm and approving an anti-inflammatory drug named Prexige, which Novartis plans to submit to the agency toward the end of this year...